Certain NSCLC Subgroups May Not Benefit From Immunotherapy

A comprehensive study exploring NSCLC subgroup responses to immunotherapy may help determine which patients are less likely to benefit from these agents.

Related Keywords

California ,United States ,San Francisco ,Mark Gramling ,Society For Immunotherapy Of Cancer ,Lung Cancer ,Ung Carcinoma ,Ancer Lung ,Biologic Therapy ,Immunotherapy ,Non Small Cell Lung Cancer ,Nsclc ,Brain Metastasis ,Metastatic Brain Tumor ,Tumor ,Malignant Head And Neck Neoplasm ,Metastasis ,Malignant Secondary Lung Neoplasm ,Etastasis Lung ,Small Cell Lung Cancer ,Cancer ,Alignant Neoplasia ,Arcinoma ,Meta Analysis ,Bioinformatics ,Brain ,Skras ,K Ras ,V Ki Ras2 Kirsten Rat Sarcoma Viral On ,